

- Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. *Autoimmunity* 2002;35:469-74.
77. Kobayashi T, Nakanishi K, Murase T, et al: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. *Diabetes* 1996;45:622-6.
 78. Maruyama T, Tanaka S, Shimada A, et al: Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. *J Clin Endocrinol Metab* 2008;93:2115-21.
 79. Johansen OE, Boehm BO, Grill V, et al: C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. *Diabetes Care* 2014;37: e11-2.
 80. Duvnjak L, Blaslov K, Lovrenčić MV, et al: Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. *Diabetes Res Clin Pract* 2016;121:119- 26.
 81. Zhao Y, Yang L, Xiang Y, et al: Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β -cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. *J Clin Endocrinol Metab* 2014;99:E876-80.
 82. Buzzetti R, Pozzilli P, Frederich R, et al: Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). *Diabetes Metab Res Rev* 2016;32:289-96.
 83. Awata T, Shimada A, Maruyama T, et al: Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). *Diabetes Ther* 2017;8:1123-34.
 84. Jones AG, McDonald TJ, Shields BM, et al: Markers of β -cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. *Diabetes Care* 2016;39:250-7.
 85. Pozzilli P, Leslie RD, Peters AL, et al: Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and-5 Trials. *Diabetes Obes Metab* 2018;20:1490-8.
 86. Kobayashi T: Multicenter prevention trial of slowly progressive IDDM with small dose of insulin (the Tokyo Study). *Diabetes Metab Res Rev* 2001; 17(Suppl.):S29.
 87. Kobayashi T, Maruyama T, Shimada A, et al: Insulin intervention to preserve β cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. *Ann NY Acad Sci* 2002;958:117-30.
 88. Thunander M, Thorgeirsson H, Törn C, et al: β -cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. *Eur J Endocrinol* 2011;164:239-45.
 89. Hals I, Grill V, Fleiner HF, et al: Favorable effects of insulin treatment for latent autoimmune diabetes in adults do not outweigh autoimmunity-induced decline in insulin release during 21 months of intervention. (Abstract #246). EASD Virtual Meeting, 2018, Berlin. Retrieved from <https://www.easd.org/virtualmeeting/home.html#!resources/favourable-effects-of-insulin-treatment-for-latent-autoimmune-diabetes-in-adults-do-not-outweigh-autoimmunity-induced-decline-in-insulin-release-during-21-months-of-intervention-f96558a6-bbbb-448f-9c68-16db5cb22132>.
 90. US National Library of Medicine. ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT02407899> (2018).
 91. Buzzetti R, Cernea S, Petrone A, et al: C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. *Diabetes* 2011;60:3067-72.
 92. Schloot NC, Cohen IR: DiaPep277® and immune intervention for treatment of type 1 diabetes. *Clin Immunol* 2013;149:307-16.
 93. Zhang Y, Lu S, Alahdal M, et al: Novel mutant P277 peptide VP to ameliorate atherogenic side-effects and to preserve anti-diabetic effects in NOD mice. *Exp Cell Res* 2018;371:399-408.
 94. Agardh CD, Cilio CM, Lethagen A, et al: Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. *J Diabetes Complications* 2005;19:238-46.
 95. Ludvigsson J. GAD65: a prospective vaccine for treating Type 1 diabetes? *Expert Opin Biol Ther* 2017;17:1033-43.